이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CStone Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

CStone Pharmaceuticals은 연평균 9.3%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 11.7%의 비율로 수입이 증가했습니다. 매출은 연평균 26.3%의 비율로 증가했습니다.

주요 정보

9.3%

수익 성장률

31.3%

EPS 성장률

Biotechs 산업 성장	11.0%
매출 성장률	26.3%
자기자본 수익률	-80.4%
순이익	-79.2%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

May 12

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Mar 04

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Jan 18

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Oct 04

수익 및 비용 분석

CStone Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:2616 수익, 비용 및 수입 (CNY Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	464	-367	382	528
30 Sep 23	472	-559	449	531
30 Jun 23	481	-750	516	534
31 Mar 23	481	-827	546	574
31 Dec 22	481	-903	576	614
30 Sep 22	454	-1,205	616	836
30 Jun 22	426	-1,508	655	1,059
31 Mar 22	335	-1,714	658	1,182
31 Dec 21	244	-1,920	661	1,305
30 Sep 21	681	-1,622	622	1,339
30 Jun 21	1,118	-1,324	583	1,373
31 Mar 21	1,079	-1,272	534	1,389
31 Dec 20	1,039	-1,221	485	1,405
30 Sep 20	519	-1,482	424	1,480
30 Jun 20	-2	-1,744	363	1,556
31 Mar 20	-1	-1,906	352	1,476
31 Dec 19	0	-2,069	341	1,396
30 Sep 19	11	-1,688	327	1,040
30 Jun 19	12	-1,246	322	725
31 Mar 19	12	-858	256	788
31 Dec 18	13	-470	191	850
30 Sep 18	13	-336	130	747
31 Dec 17	10	-107	39	213

양질의 수익: 2616 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 2616 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 2616 은(는) 수익성이 없지만 지난 5년 동안 연간 9.3% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 2616 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 2616 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 22.1% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 2616 현재 수익성이 없기 때문에 마이너스 자본 수익률( -80.39% )을 갖습니다.

CStone Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022

CStone Pharmaceuticals to Report Fiscal Year 2021 Results on Mar 24, 2022

CStone Pharmaceuticals to Report Fiscal Year 2020 Results on Mar 25, 2021

Recent updates

CStone Pharmaceuticals Announces Change of Joint Company Secretary

CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024

CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024

CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

CStone Announces the Availability of RET Inhibitor GAVRETO® (palsetinib) Manufacturing Localization Application by Center for Drug Evalence of China NMPA

Forecast to breakeven in 2026

CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Consensus EPS estimates fall by 38%

New minor risk - Share price stability

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma

CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma

CEO, Senior VP & Chief Medical Officer recently bought HK$385k worth of stock

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

CStone Pharmaceuticals Announces Receipt of GCP Inspection Notification from the European Medicines Agency Regarding the Marketing Authorization Application

CEO, Senior VP & Chief Medical Officer recently bought HK$1.1m worth of stock

CStone Pharmaceuticals Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023

CStone Pharmaceuticals Announces GAVRETO SNDA Approval by China NMPA for First-Line Treatment of Patients with Locally Advanced or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer

CEO, Senior VP & Chief Medical Officer recently bought HK$676k worth of stock

CStone Pharmaceuticals Announces New Data on AYVAKIT (Avapritinib) in Patients with Advanced Gastrointestinal Stromal Tumor at ASCO 2023

CEO, Senior VP & Chief Medical Officer recently bought HK$285k worth of stock

CEO, Senior VP & Chief Medical Officer recently bought HK$457k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2024

No longer forecast to breakeven

CStone Pharmaceuticals has completed a Follow-on Equity Offering in the amount of HKD 392.8784 million.

CStone Pharmaceuticals Provides Earning Guidance for the Year Ended December 31, 2022

Cstone Pharmaceuticals Announces Management Changes

CStone Pharmaceuticals Announces the NDA Approval of GAVRETO (Pralsetinib) for the Treatment of Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer and Ret-Altered Thyroid Cancer in Taiwan, China

CStone Pharmaceuticals Announces Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints

CStone Pharmaceuticals Announces Results from the Navigator China Bridging Study of AYVAKIT(avapritinib) Published in the Oncologist

Cstone Pharmaceuticals Presents Updated Data for Gavreto (Pralsetinib) in Chinese Patients with Ret-Fusion Positive Non-Small Cell Lung Cancer at Esmo Asia Congress 2022

CEO, Senior VP & Chief Medical Officer recently bought HK$2.2m worth of stock

Less than half of directors are independent

Forecast to breakeven in 2024

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

National Medical Products Administration of China Accepts and Grants Priority Review to the Supplemental New Drug Application (sNDA) for sugemalimab of CStone Pharmaceuticals

CEO, Senior VP & Chief Medical Officer recently bought HK$668k worth of stock

CStone Pharmaceuticals Announces Acceptance of Priority Review to the Supplemental New Drug Application for Sugemalimab

CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022

CStone Pharmaceuticals Presents Updated Results of Registrational Study of Sugemalimab in Patients with Stage III NSCLC at WCLC 2022

CStone Pharmaceuticals Announces Executive Changes

Hong Kong, China Approve GAVRETO of CStone Pharmaceuticals

CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

Forecast to breakeven in 2024

CStone Pharmaceuticals, Annual General Meeting, Jun 30, 2022

CStone Pharmaceuticals Presents Pre-Specified Overall Survival Data of Sugemalimab for First-Line Treatment of Stage Iv Non-Small Cell Lung Cancer At Asco 2022

CStone Pharmaceuticals Presents Updated Results of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma at ASCO 2022

CStone Pharmaceuticals Presents Clinical Results of Sugemalimab in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma Via an Oral Abstract Session At ASCO 2022

Less than half of directors are independent

CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC

CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of Tibsovo

CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific Antibody-Based Therapeutic Candidate CS2006/NM21-1480 At the American Association for Cancer Research (AACR) Annual Meeting 2022

CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Clinical Trial of Cs5001, A Potential Global Best-In-Class Ror1-Targeting ADC

CStone Pharmaceuticals to Report Fiscal Year 2021 Results on Mar 24, 2022

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China

CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibsovo® (Ivosidenib Tablets) as A New Precision Therapy for Patients with Acute Myeloid Leukemia

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

CStone Pharmaceuticals Announces Two Key Phase 3 Registrational Clinical Trials of Sugemalimab Completed Patient Enrollment

Cstone Pharmaceuticals Announces the Registrational Clinical Study Results of Sugemalimab in Stage IV Non-Small Cell Lung Cancer Published in the Lancet Oncology

CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response Rate (ORR) in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)